Toll-like receptor 4 (TLR4) signaling complex (TLR4)

The Toll-like receptor 4 (TLR4) signaling complex is a fundamental component of the innate immune system, primarily responsible for the detection of lipopolysaccharide (LPS) from Gram-negative bacteria (1.3.1, 1.3.5). This multiprotein complex consists of the transmembrane receptor TLR4, the essential co-receptor Myeloid Differentiation factor 2 (MD-2), and the accessory protein CD14, which together coordinate the binding and recognition of bacterial endotoxins (1.3.4, 1.4.1). Upon activation, the complex initiates two distinct intracellular cascades: the MyD88-dependent pathway at the plasma membrane and the TRIF-dependent pathway following receptor endocytosis, leading to the production of pro-inflammatory cytokines and type I interferons (1.2.2, 1.4.4). While these responses are vital for host defense, dysregulation of the LPS-TLR4 axis is heavily implicated in the pathogenesis of sepsis, chronic inflammatory disorders, and various metabolic and neurodegenerative diseases (1.1.1, 1.2.1). Therapeutic strategies targeting this complex include antagonists like Eritoran and TAK-242, which aim to mitigate hyper-inflammation, and agonists like monophosphoryl lipid A (MPLA), which serve as potent vaccine adjuvants (1.1.4, 1.2.1). Despite its clear therapeutic potential, clinical development of TLR4 modulators has faced significant challenges due to the complex, context-dependent nature of TLR4 signaling in human health and disease (1.2.1, 1.3.4).

Other names

LPS receptor complexTLR4-MD2-CD14 complexCD284Toll-like receptor 4LPS-TLR4 axisTLR4/LY96 complex

Antagonism by blocking lipopolysaccharide (LPS) binding to the MD-2 co-receptor or preventing TLR4 dimerization; agonism by mimicking lipid A to stimulate innate immune pathways for vaccine adjuvancy; intracellular inhibition by binding to the TLR4 cytoplasmic domain to disrupt adapter protein recruitment.